Abzena and ProteoNic Expand Partnership in October 2024
- ProteoNic and Abzena have expanded their partnership to include the 2G UNic® technology as a standard offering.
- The AbZelectPRO™ platform has demonstrated significant improvements in protein production efficiency and reduced development timelines.
- This collaboration aims to enhance the development of high-yielding mammalian cell lines for Abzena's customers.
In Leiden, The Netherlands, on October 1, 2024, ProteoNic announced an expanded partnership with Abzena, a prominent contract development and manufacturing organization (CDMO) specializing in complex biologics. This collaboration follows the successful launch of AbZelectPRO™, a cell line development platform that integrates ProteoNic's 2G UNic® vector technology with Abzena's host cell line. The integration has resulted in significant advancements in protein production efficiency, achieving levels up to 8g/L and reducing timelines for developing research cell banks to just 10 weeks. The decision to standardize this combined platform for all customers stems from the positive outcomes observed over the past 10 months. ProteoNic's technology has been instrumental in enhancing protein expression, particularly for challenging targets like bi-specifics and fusion proteins. The 2G UNic® vector technology has already been referenced in various investigational new drug applications and clinical trials, showcasing its effectiveness in the biopharmaceutical industry. Abzena's commitment to utilizing ProteoNic's technology globally will provide a robust platform for developing high-yielding mammalian cell lines, catering to a diverse customer base. The partnership aims to support a fast-track path to clinical trials for clients, leveraging the successful integration of both companies' platforms. This expanded agreement not only highlights the value of the collaboration but also emphasizes the importance of innovative solutions in the biotech and biopharma sectors, ultimately driving projects forward and enhancing the development of new medicines.